Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don't Rush To Reorganize FDA, McClellan Says

Executive Summary

Former commissioner says agency has to think about getting biggest bang for the buck when considering a reorganization to disease-focused teams.


Related Content

New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
US FDA May Create Immunology, Neuroscience Centers Of Excellence
US FDA Drug Office Reform: 'Everything' Is On The Table
Gottlieb Promotes 'Team' Work For Product Reviews
FDA's Oncology Center Of Excellence On Equal Terms With CDER In New Org Chart
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA Generics Office Drinks Super Serum, Then Shrinks
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts